stoxline Quote Chart Rank Option Currency Glossary
  
Halozyme Therapeutics, Inc. (HALO)
43.82  -0.1 (-0.23%)    05-24 16:00
Open: 43.65
High: 44.02
Volume: 869,022
  
Pre. Close: 43.92
Low: 42.9601
Market Cap: 5,577(M)
Technical analysis
2024-05-27 4:46:21 PM
Short term     
Mid term     
Targets 6-month :  53.91 1-year :  62.97
Resists First :  46.15 Second :  53.91
Pivot price 43.87
Supports First :  41.09 Second :  37.97
MAs MA(5) :  44.74 MA(20) :  42.7
MA(100) :  38.88 MA(250) :  38.65
MACD MACD :  1.3 Signal :  1.3
%K %D K(14,3) :  72 D(3) :  81.3
RSI RSI(14): 58
52-week High :  46.15 Low :  31.86
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ HALO ] has closed above bottom band by 49.1%. Bollinger Bands are 37.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 44.11 - 44.38 44.38 - 44.58
Low: 42.33 - 42.68 42.68 - 42.94
Close: 43.35 - 43.88 43.88 - 44.27
Company Description

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Headline News

Mon, 27 May 2024
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Artisan Partners Limited Partnership - MarketBeat

Sun, 26 May 2024
Analyzing Entera Bio (NASDAQ:ENTX) & Halozyme Therapeutics (NASDAQ:HALO) - Defense World

Sat, 25 May 2024
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Ontario Teachers Pension Plan Board - MarketBeat

Fri, 24 May 2024
Halozyme Therapeutics (HALO) Down 19.3% Since Last Earnings Report: Can It Rebound? - Yahoo Canada Shine On

Thu, 23 May 2024
Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World

Thu, 23 May 2024
Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 10,000 Shares of Stock - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 127 (M)
Shares Float 126 (M)
Held by Insiders 1.1 (%)
Held by Institutions 99.5 (%)
Shares Short 8,410 (K)
Shares Short P.Month 7,890 (K)
Stock Financials
EPS 2.41
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.39
Profit Margin 36.9 %
Operating Margin 48.7 %
Return on Assets (ttm) 13.4 %
Return on Equity (ttm) 261.6 %
Qtrly Rev. Growth 20.7 %
Gross Profit (p.s.) 0
Sales Per Share 6.78
EBITDA (p.s.) 3.6
Qtrly Earnings Growth 106.9 %
Operating Cash Flow 431 (M)
Levered Free Cash Flow 320 (M)
Stock Valuations
PE Ratio 18.18
PEG Ratio 0.4
Price to Book value 31.3
Price to Sales 6.46
Price to Cash Flow 12.93
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android